Patents by Inventor Susan K. Keay
Susan K. Keay has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9085604Abstract: A novel antiproliferative factor comprising a glycopeptide is disclosed. In specific embodiments, the novel antiproliferative factor is associated with the bladder. Compositions, diagnostic kits and reagents, and methods of using the compounds for identifying and/or treating interstitial cystitis and cancer are disclosed.Type: GrantFiled: December 13, 2007Date of Patent: July 21, 2015Assignees: University of Maryland, Baltimore, The United States of America as represented by the Secretary of the Department of Health and Human Services, The United Sates of America as Represented by the Department of Veterans AffairsInventors: Susan K. Keay, Zoltan Szekely, Thomas Conrads, Timothy Veenstra, Maria Michejda
-
Patent number: 9079936Abstract: Derivatives of a novel antiproliferative factor comprising a glycopeptide is disclosed. In specific embodiments, the novel antiproliferative factor is associated with the bladder. Compositions, diagnostic kits and reagents, and methods of using the compounds for identifying and/or treating interstitial cystitis and cancer are disclosed. In particular embodiments, the glycopeptide comprises D-proline.Type: GrantFiled: August 18, 2009Date of Patent: July 14, 2015Assignees: University of Maryland, Baltimore, The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services, The United States of America as Represented by the Department of Veterans AffairsInventors: Susan K. Keay, Zoltan Szekely, Maria Michejda
-
Patent number: 8912146Abstract: Derivatives of bladder epithelial antiproliferative factor and methods of using them are disclosed. In specific embodiments, the glycopeptide compositions are useful for the treatment and/or prevention of medical conditions, including cancer. In other embodiments, there are compositions and methods related to treatment of bladder conditions. In particular embodiments, the glycopeptide comprises D-pipecolic acid or L-pipecolic acid.Type: GrantFiled: August 18, 2009Date of Patent: December 16, 2014Assignees: University of Maryland, Baltimore, The Department of Health and Human Services, The United States of America as Represented by the Department of Veterans AffairsInventors: Susan K. Keay, Zoltan Szekely, Piotr Kaczmarek, Maria Michejda
-
Patent number: 8680056Abstract: A novel antiproliferative factor comprising a glycopeptide is disclosed. In specific embodiments, the novel antiproliferative factor is associated with the bladder. Compositions, diagnostic kits and reagents, and methods of using the compounds for identifying and/or treating interstitial cystitis and cancer are disclosed.Type: GrantFiled: May 3, 2007Date of Patent: March 25, 2014Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University of Maryland, Baltimore, The United States of America as Represented by the Department of Veterans AffairsInventors: Susan K. Keay, Zoltan Szekely, Thomas Conrads, Timothy Veenstra, Maria Michejda
-
Patent number: 8404655Abstract: The invention generally concerns inhibition of a molecule that has a role in post-translational modification of a receptor for antiproliferative factor (APF) of bladder epithelial cells, thereby modulating the APF. In particular, inhibition of DHHC2 activity and/or ZDHHC2 expression results in modulation of APF receptor activity, and in specific aspects such modulation is therapeutic and/or preventative for a bladder condition, such as interstitial cystitis. In addition, inhibition of CKAP4 palmitoylation in certain cases also decreases its activity as a tPA receptor on smooth muscle cells or surfactant A on type II pneumocytes, and/or generally inhibits its function as a cell membrane receptor, cell chaperone molecule, and/or membrane trafficking agent.Type: GrantFiled: May 16, 2008Date of Patent: March 26, 2013Assignees: University of Florida Research Foundation, Inc., University of Maryland, The United States of America as represented by the Department of Veterans AffairsInventors: Susan K. Keay, David Zacharias, Sonia L. Planey
-
Publication number: 20120094933Abstract: Derivatives of bladder epithelial antiproliferative factor and methods of using them are disclosed. In specific embodiments, the glycopeptide compositions are useful for the treatment and/or prevention of medical conditions, including cancer. In other embodiments, there are compositions and methods related to treatment of bladder conditions. In particular embodiments, the glycopeptide comprises D-pipecolic acid or L-pipecolic acid.Type: ApplicationFiled: August 18, 2009Publication date: April 19, 2012Inventors: Christopher Michejda, Maria Michejda, Susan K. Keay, Zoltan Szekely, Piotr Kaczmarek
-
Publication number: 20100190684Abstract: The invention generally concerns inhibition of a molecule that has a role in post-translational modification of a receptor for antiproliferative factor (APF) of bladder epithelial cells, thereby modulating the APF. In particular, inhibition of DHHC2 activity and/or ZDHHC2 expression results in modulation of APF receptor activity, and in specific aspects such modulation is therapeutic and/or preventative for a bladder condition, such as interstitial cystitis. In addition, inhibition of CKAP4 palmitoylation in certain cases also decreases its activity as a tPA receptor on smooth muscle cells or surfactant A on type II pneumocytes, and/or generally inhibits its function as a cell membrane receptor, cell chaperone molecule, and/or membrane trafficking agent.Type: ApplicationFiled: May 16, 2008Publication date: July 29, 2010Applicant: The University of Maryland, BaltimoreInventors: Susan K. Keay, David Zacharias, Sonia L. Planey
-
Publication number: 20100055113Abstract: The present invention concerns the receptor for antiproliferative factor (APF) from bladder epithelial cells. In particular, there are compositions and methods for modulating APF, APF receptor, and/or the binding of APF to APF receptor. Agents that interfere with the binding of APF to its receptor or agents that enhance the binding of APF to its receptor are contemplated. In specific aspects, certain compositions are employed for a therapeutic purpose, such as interstitial cystitis or cancer, for example.Type: ApplicationFiled: July 27, 2007Publication date: March 4, 2010Applicants: The University of Maryland, Baltimore, Government of the United States of America, as rep resented by the Secretary of the Dept. of HealthInventors: Susan K. Keay, Christopher Michejda, Gillian Tocci, Thomas Conrads, Timothy Veenstra, Brian Lewis Hood
-
Publication number: 20100041588Abstract: Derivatives of a novel antiproliferative factor comprising a glycopeptide is disclosed. In specific embodiments, the novel antiproliferative factor is associated with the bladder. Compositions, diagnostic kits and reagents, and methods of using the compounds for identifying and/or treating interstitial cystitis and cancer are disclosed. In particular embodiments, the glycopeptide comprises D-proline.Type: ApplicationFiled: August 18, 2009Publication date: February 18, 2010Inventors: Susan K. Keay, Christopher Michejda, Maria Michejda, Zoltan Szekely
-
Publication number: 20090148505Abstract: A novel antiproliferative factor comprising a glycopeptide is disclosed. In specific embodiments, the novel antiproliferative factor is associated with the bladder. Compositions, diagnostic kits and reagents, and methods of using the compounds for identifying and/or treating interstitial cystitis and cancer are disclosed.Type: ApplicationFiled: December 13, 2007Publication date: June 11, 2009Applicant: University of MarylandInventors: Susan K. Keay, Christopher Michejda, Zoltan Szekely, Thomas P. Conrads, Timothy D. Veenstra, Maria Michejda
-
Patent number: 6376197Abstract: Interstitial cystitis (IC) is a chronic bladder disease for which the exact etiology is unknown and for which there is no reliably effective treatment. However, it is known that the bladder epithelium is often abnormal in IC. We discovered that normal, adult, human bladder epithelial cells are inhibited from proliferating by an anti-proliferative factor (APF) present in IC urine specimens. Inhibited proliferation may cause epithelial abnormalities characteristic of IC such as ulcerations and multiple tears in the bladder epithelium. We further discovered that levels of heparin binding—epidermal growth factor-like growth factor (HB-EGF), a factor known be important for epithelial cell proliferation and wound healing in other tissues, are abnormally low in the urine of patients suffering from IC as compared to asymptomatic controls or patients with acute bacterial cystitis. The invention herein is directed to the use of urine levels of HB-EGF as a diagnostic marker for IC.Type: GrantFiled: May 22, 2000Date of Patent: April 23, 2002Assignee: University of Maryland, BaltimoreInventors: Susan K. Keay, John W. Warren, Michael K. Hise
-
Publication number: 20020016443Abstract: The invention relates to a novel antiproliferative factor (APF) present in urine of patients with interstitial cystitis (IC). APF is useful as a marker for disease activity and its antagonists are useful as therapeutic medicaments for IC and other conditions associated with elevated APF. APF and its agonists are useful in the treatment of diseases associated with cell proliferation, such as bladder cancer.Type: ApplicationFiled: April 21, 2001Publication date: February 7, 2002Inventors: Susan K. Keay, John W. Warren, Michael Kleinberg, Michael K. Hise
-
Patent number: 6156522Abstract: Interstitial cystitis (IC) is a chronic bladder disease for which the exact etiology is unknown and for which there is no reliably effective treatment. However, it is known that the bladder epithelium is often abnormal in IC. We discovered that normal, adult, human bladder epithelial cells are inhibited from proliferating by an anti-proliferative fact (APF) present in IC urine specimens. Inhibited proliferation may cause epthelial abnormalities characteristic of IC such as ulcerations and multiple tears in the bladder epithelium. We further discovered that levels of heparin binding--epidermal growth factor-like growth fact (HB-EGF), a factor known be important for epithelial cell proliferation and wound healing in other tissues, are abnormally low in the urine of patients suffering from IC as compared to asymptomatic controls or patients with acute bacterial cystitis. The invention herein is directed to the use of urine levels of HB-EGF as a diagnostic marker for IC.Type: GrantFiled: July 2, 1998Date of Patent: December 5, 2000Assignee: University of Maryland BaltimoreInventors: Susan K. Keay, John W. Warren, Michael K. Hise